Johnson & Johnson (JNJ)vsTwist Bioscience Corp (TWST)
JNJ
Johnson & Johnson
$276.25
+1.43%
HEALTHCARE · Cap: $657.68B
TWST
Twist Bioscience Corp
$120.79
+0.15%
HEALTHCARE · Cap: $9.58B
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 22905% more annual revenue ($99.33B vs $431.80M). JNJ leads profitability with a 16.2% profit margin vs -31.7%. JNJ earns a higher WallStSmart Score of 54/100 (C-).
JNJ
Buy54
out of 100
Grade: C-
TWST
Avoid28
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for JNJ.
Margin of Safety
+57.1%
Fair Value
$115.62
Current Price
$120.79
$5.17 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Strong operational efficiency at 25.7%
Generating 6.4B in free cash flow
Conservative balance sheet, low leverage
Revenue surging 23.2% year-over-year
Areas to Watch
Trading at 8.2x book value
Weak financial health signals
Expensive relative to growth rate
Premium valuation, high expectations priced in
Trading at 17.0x book value
0.0% earnings growth
ROE of -30.7% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Operating Margin, Free Cash Flow. Profitability is solid with margins at 16.2% and operating margin at 25.7%.
Bull Case : TWST
The strongest argument for TWST centers on Debt/Equity, Revenue Growth. Revenue growth of 23.2% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are Price/Book, Piotroski F-Score, PEG Ratio. A P/E of 41.5x leaves little room for execution misses.
Bear Case : TWST
The primary concerns for TWST are Price/Book, EPS Growth, Return on Equity.
Key Dynamics to Monitor
JNJ profiles as a mature stock while TWST is a growth play — different risk/reward profiles.
TWST carries more volatility with a beta of 2.19 — expect wider price swings.
TWST is growing revenue faster at 23.2% — sustainability is the question.
JNJ generates stronger free cash flow (6.4B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (54/100 vs 28/100), backed by strong 16.2% margins. TWST offers better value entry with a 57.1% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Twist Bioscience Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company is headquartered in South San Francisco, California.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?